Already boasting a positive recommendation overseas, Novo’s hemophilia A newcomer Frehemgo will have to wait a while longer ...

Attruby maker BridgeBio is re-upping its “Don’t Pass on Your Heart Health” campaign with a fresh new beat.  | BridgeBio's YouTube awareness push to lead up to World Amyloidosis Day features a ...

The FDA has warned Evolus over an Instagram reel that made the “especially problematic” suggestion of blurred lines between a ...

Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...

INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

Just months after trimming jobs in New Jersey following an acquisition, BioMarin is laying off 117 employees in California as ...